Quick Answer
Lexaria Bioscience Corp. reported Total Revenue of $705.9 thousand for fiscal year 2025.
Lexaria Bioscience Corp. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Total Revenue | $705.9K +52.0% |
$464.3K +105.2% |
$226.2K -11.4% |
$255.4K -64.7% |
$722.7K +129.6% |
$314.8K +41.4% |
| Revenue (ASC 606) | — | — | — | — | — | $384.5K +72.7% |
| Net Income | -$11.90M -105.4% |
-$5.80M +13.0% |
-$6.66M +8.3% |
-$7.27M -80.5% |
-$4.03M +1.4% |
-$4.08M +1.8% |
| Diluted EPS | -$0.66 -40.4% |
-$0.47 +53.5% |
-$1.01 | — | — | — |
| Total Assets | $4.18M -52.9% |
$8.87M +187.5% |
$3.08M -60.6% |
$7.83M -41.0% |
$13.27M +369.1% |
$2.83M +5.7% |
| Cash and Equivalents | — | — | — | $5.81M -46.8% |
$10.92M +743.9% |
$1.29M +0.7% |
| Stockholders Equity | $2.99M -62.8% |
$8.04M +164.0% |
$3.04M -61.7% |
$7.95M -40.1% |
$13.27M +434.4% |
$2.48M -0.3% |
| R&D Expense | $8.24M +249.0% |
$2.36M -35.6% |
$3.67M +99.0% |
$1.84M +45.9% |
$1.26M +226.3% |
$387.1K -30.3% |
| Operating Income | -$11.88M -106.5% |
-$5.75M +12.0% |
-$6.53M +1.3% |
-$6.62M -16.4% |
-$5.69M | — |
| Gross Profit | $703.2K +53.1% |
$459.5K -14.7% |
$538.3K +193.3% |
$183.6K -66.5% |
$547.4K +154.1% |
$215.4K +7.9% |
| Shares Outstanding | 19.56M +23.7% |
15.81M +95.4% |
8.09M +36.0% |
5.95M +3.9% |
5.73M +90.8% |
3.00M -96.2% |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | November 30, 2025 | $0.00 | -100.0% | -100.0% |
| Revenue (ASC 606) | May 31, 2021 | $204.1K | +460.2% | +6.3% |
| Net Income | November 30, 2025 | -$1.60M | +41.0% | +57.9% |
| Diluted EPS | November 30, 2025 | -$0.07 | +56.2% | +66.7% |
| Total Assets | November 30, 2025 | $6.05M | -38.2% | +44.9% |
| Cash and Equivalents | February 28, 2023 | $3.27M | -60.9% | -27.8% |
| Stockholders Equity | November 30, 2025 | $4.91M | -49.7% | +64.3% |
| R&D Expense | November 30, 2025 | $671.3K | -65.6% | -75.3% |
| Operating Income | November 30, 2025 | -$1.57M | +41.5% | +58.0% |
| Gross Profit | November 30, 2025 | $0.00 | -100.0% | -100.0% |
| Shares Outstanding | November 30, 2025 | 22.23M | +27.3% | +14.2% |
- Lexaria Bioscience Corp. reported Total Revenue of $705.9 thousand for fiscal year 2025.
- Lexaria Bioscience Corp. showed an increase of +52.0% in Total Revenue compared to the prior fiscal year.
- Lexaria Bioscience Corp. reported Revenue (ASC 606) of $384.5 thousand for fiscal year 2020.
- Lexaria Bioscience Corp. showed an increase of +72.7% in Revenue (ASC 606) compared to the prior fiscal year.
- Lexaria Bioscience Corp. reported Net Income of -$11.90 million for fiscal year 2025.
- Lexaria Bioscience Corp. showed a decrease of -105.4% in Net Income compared to the prior fiscal year.
- Lexaria Bioscience Corp. reported Diluted EPS of $0.66 per share (loss) for fiscal year 2025.
- Lexaria Bioscience Corp. showed a decrease of -40.4% in Diluted EPS compared to the prior fiscal year.
- Lexaria Bioscience Corp. reported Total Assets of $4.18 million for fiscal year 2025.
- Lexaria Bioscience Corp. showed a decrease of -52.9% in Total Assets compared to the prior fiscal year.
- Lexaria Bioscience Corp. reported Cash and Equivalents of $5.81 million for fiscal year 2022.
- Lexaria Bioscience Corp. showed a decrease of -46.8% in Cash and Equivalents compared to the prior fiscal year.
- Lexaria Bioscience Corp. reported Stockholders Equity of $2.99 million for fiscal year 2025.
- Lexaria Bioscience Corp. showed a decrease of -62.8% in Stockholders Equity compared to the prior fiscal year.
- Lexaria Bioscience Corp. reported R&D Expense of $8.24 million for fiscal year 2025.
- Lexaria Bioscience Corp. showed an increase of +249.0% in R&D Expense compared to the prior fiscal year.
- Lexaria Bioscience Corp. reported Operating Income of -$11.88 million for fiscal year 2025.
- Lexaria Bioscience Corp. showed a decrease of -106.5% in Operating Income compared to the prior fiscal year.
- Lexaria Bioscience Corp. reported Gross Profit of $703.2 thousand for fiscal year 2025.
- Lexaria Bioscience Corp. showed an increase of +53.1% in Gross Profit compared to the prior fiscal year.
- Lexaria Bioscience Corp. reported Shares Outstanding of 19.56 million shares for fiscal year 2025.
- Lexaria Bioscience Corp. showed an increase of +23.7% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: